
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. is experiencing promising growth trends, with an anticipated operating margin expansion of over 16%, surpassing prior projections. The company is poised for significant revenue increases, projecting a 35.2% year-over-year growth in US organ transplant volume and a 40.5% rise in US sales for Q4, which exceed consensus estimates. Additionally, favorable factors such as new product launches, accelerating adoption rates in heart and lung transplants, and stronger international growth contribute to the overall positive outlook for TransMedics Group’s performance.
Bears say
TransMedics Group Inc. has reported Q3 product revenues of $87.7 million and service revenues of $56.1 million, both showing year-over-year growth of over 30%, yet falling short of consensus estimates by approximately $1 million, indicating potential challenges in market penetration and sales force scalability. Furthermore, the company's daily flights and flight hours experienced sequential declines, aligning more with Q1/25 metrics rather than showing sustained growth, which raises concerns about operational efficiency and market presence. Additionally, the firm faces various risks including competition, regulatory challenges, and the effectiveness of its commercialization strategy, all of which contribute to a negative outlook amid the marginal top-line miss and the downward adjustment in share value.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares